Patents Represented by Attorney, Agent or Law Firm Law Offices of Jane Massey Licata
  • Antisense inhibition of fra-1 expression
    Patent number: 6124133
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of fra-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fra-1. Methods of using these compounds for modulation of fra-1 expression and for treatment of diseases associated with expression of fra-1 are provided.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Jennifer K. Taylor, Lex M. Cowsert
  • Antisense modulation of PDK-1 expression
    Patent number: 6124272
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PDK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PDK-1. Methods of using these compounds for modulation of PDK-1 expression and for treatment of diseases associated with expression of PDK-1 are provided.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: September 26, 2000
    Assignee: Isis Pharmaceutical Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • AMP activated protein kinase
    Patent number: 6124125
    Abstract: Polynucleotides of AMPK .alpha.1, AMPK .beta. and AMPK .gamma. and polypeptides and biologically active fragments encoded thereby are provided. Vectors and host cells containing these polynucleotides are also provided. In addition, methods of preparing polypeptides and antibodies targeted against these polypepitdes are provided.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: September 26, 2000
    Assignees: Trustees of Dartmouth College, St. Vincents Institute of Medical Research
    Inventors: Bruce E. Kemp, David I. Stapleton, Kenneth I. Mitchelhill, Lee A. Witters
  • Antisense modulation of SHP-1 expression
    Patent number: 6121047
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SHP-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SHP-1. Methods of using these compounds for modulation of SHP-1 expression and for treatment of diseases associated with expression of SHP-1 are provided.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: September 19, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert
  • Antisense oligonucleotide inhibition of ras
    Patent number: 6117848
    Abstract: Compositions and methods are provided for the modulation of ras expression. Oligonucleotides are provided which are targeted to nucleic acids encoding human ras. Oligonucleotides specifically hybridizable with mRNA encoding human H-ras, Ki-ras and N-ras are provided. Such oligonucleotides can be used for therapeutics and diagnostics as well as for research purposes. Methods are also disclosed for modulating ras gene expression in cells and tissues using the oligonucleotides provided, and for specific modulation of expression of activated ras. Methods for diagnosis, detection and treatment of conditions associated with ras are also disclosed.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: September 12, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert, Muthiah Manoharan
  • Methods of modulating tumor necrosis factor .alpha.-induced expression of cell adhesion molecules
    Patent number: 6114517
    Abstract: Methods are provided for inhibiting the expression of cell adhesion molecules using inhibitors of signaling molecules involved in human TNF-.alpha. signaling. These inhibitors include monoclonal antibodies, peptide fragments, small molecule inhibitors, and, preferably, antisense oligonucleotides. Methods for treatment of diseases, particularly inflammatory and immune diseases, associated with overexpression of cell adhesion molecules are provided.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: September 5, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Xiaoxing S. Xu
  • Enhanced antisense modulation of ICAM-1
    Patent number: 6111094
    Abstract: The present invention provides compositions and methods for detecting and modulating levels of intercellular adhesion molecule-1 (ICAM-1) proteins, including human ICAM-1.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: August 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Thomas P. Condon, Shin Cheng Flournoy
  • Controlled release device based on aqueous-organic partitioning in porous membranes
    Patent number: 6110481
    Abstract: A novel controlled release device employing microporous membranes with or without a nonporous coating and aqueous-organic partitioning of the bioreactive substances to be delivered is provided. Devices and methods for delivering pharmaceuticals, pest-control substances, hormones, nutrients and fragrances to humans, animals or any environment are also provided.
    Type: Grant
    Filed: March 4, 1994
    Date of Patent: August 29, 2000
    Assignee: Trustees of the Stevens Institute of Technology
    Inventors: Kamalesh K. Sirkar, Stephanie Farrell, Rahul Basu
  • Antisense inhibition of G-alpha-S1 expression
    Patent number: 6110664
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-S1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-S1. Methods of using these compounds for modulation of G-alpha-S1 expression and for treatment of diseases associated with expression of G-alpha-S1 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: August 29, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Antisense inhibition of G-alpha-16 expression
    Patent number: 6107091
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of G-alpha-16. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding G-alpha-16. Methods of using these compounds for modulation of G-alpha-16 expression and for treatment of diseases associated with expression of G-alpha-16 are provided.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: August 22, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Lex M. Cowsert
  • Preparation consisting of a surface-adhering, film-like or wafer-like administration form
    Patent number: 6106930
    Abstract: A preparation consisting of a sheet-like, film-like or wafer-like administration form with a coding in the form of characters and/or graphic symbols or patterns for identifying the substances affecting flavor or odor and/or the therapeutic or curative substances which can be released therefrom during use is characterized in that the coding is formed by surface areas of differing thickness.
    Type: Grant
    Filed: May 5, 1998
    Date of Patent: August 22, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Karin Ludwig
  • Antisense inhibition of PI3K p85 expression
    Patent number: 6100090
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of PI3K p85. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PI3K p85. Methods of using these compounds for modulation of PI3K p85 expression and for treatment of diseases associated with expression of PI3K p85 are provided.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: August 8, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense inhibition of human mek1 expression
    Patent number: 6096543
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MEK1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MEK1. Methods of using these compounds for modulation of MEK1 expression and for treatment of diseases associated with expression of MEK1 are provided.
    Type: Grant
    Filed: November 20, 1998
    Date of Patent: August 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Lex M. Cowsert
  • Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
    Patent number: 6096722
    Abstract: Compositions and methods are provided for the modulation of expression of cellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. Methods of modulating expression of cellular adhesion molecules are provided, as are methods of treating conditions associated with cellular adhesion molecules. In a preferred embodiment, the cellular adhesion molecule is ICAM-1, and a preferred antisense sequence targeted to human ICAM-1 is demonstrated to have clinical utility in several disease indications.
    Type: Grant
    Filed: May 27, 1998
    Date of Patent: August 1, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli, Brenda Baker
  • Oligonucleotide modulation of cell adhesion
    Patent number: 6093811
    Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: July 25, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Christopher K. Mirabelli
  • Antisense oligonucleotide modulation of raf gene expression
    Patent number: 6090626
    Abstract: Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. In preferred embodiments, the oligonucleotides are targeted to mRNA encoding human c-raf or human A-raf. The oligonucleotides may have chemical modifications at one or more positions and may be chimeric oligonucleotides. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: July 18, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brett P. Monia, Russell T. Boggs
  • Antisense modulation of X-linked inhibitor of apoptosis expression
    Patent number: 6087173
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of X-linked inhibitor of apoptosis. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding X-linked inhibitor of apoptosis. Methods of using these compounds for modulation of X-linked inhibitor of apoptosis expression and for treatment of diseases associated with expression of X-linked inhibitor of apoptosis are provided.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: July 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: C. Frank Bennett, Elizabeth J. Ackermann, Lex M. Cowsert
  • Antisense oligonucleotide modulation of human thymidylate synthase expression
    Patent number: 6087489
    Abstract: Compounds, compositions and methods are provided for modulating the expression of human thymidylate synthase. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding thymidylate synthase. Methods of using these oligonucleotides for modulation of thymidylate synthase expression and for treatment of diseases such as cancers believed to be responsive to modulation of thymidylate synthase expression are provided.
    Type: Grant
    Filed: June 2, 1998
    Date of Patent: July 11, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventor: Nicholas M. Dean
  • Liposomal oligonucleotide compositions for modulating RAS gene expression
    Patent number: 6083923
    Abstract: Pharmaceutical compositions comprising sterically stabilized liposomes containing antisense oligonucleotides are provided for the modulation of expression of the human ras gene in both the normal (wildtype) and activated (mutant) forms.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: July 4, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Gregory E. Hardee, Richard S. Geary, Arthur Levin, Michael V. Templin, Randy Howard, Rahul C. Mehta
  • Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (TNF-.alpha.) expression
    Patent number: 6080580
    Abstract: Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-.alpha. (TNF-.alpha.). Antisense oligonucleotides targeted to nucleic acids encoding TNF-.alpha. are preferred. Methods of using these oligonucleotides for inhibition of TNF-.alpha. expression and for treatment of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-.alpha. are provided.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: June 27, 2000
    Assignee: Isis Pharmaceuticals Inc.
    Inventors: Brenda F. Baker, C. Frank Bennett, Madeline M. Butler, William R. Shanahan, Jr.